CMFRI adjudged as best research institute under ICAR
CMFRI wins ICAR’s highest award
The Central Marine Fisheries Research Institute (CMFRI) has been adjudged as the best research institute of the Indian Council of Agricultural Research (ICAR). The CMFRI won the Sardar Patel Outstanding ICAR institutions award, the highest award of the ICAR in the category of the large institutions with a cash prize of Rs 10 Lakhs, a Silver Plaque, Certificate and Citation.This is in recognition of CMFRI’s excellent performance in marine fisheries research during the period from 2014 to 2019.
This is the second time CMFRI bagging this prestigious award. Various cutting edge research activities including development of mariculture technologies such as open sea cage fish farming, seaweed farming, integrated multi-trophic aquaculture (IMTA) and breeding and seed production technologies for marine food fish and ornamental fishes which were aimed to enhance the income of fishermen helped CMFRI achieving the highest ranking among more than 110 agricultural and allied research institutes in the country. CMFRI’s efforts on preparing a range of policy guidelines, including the works on minimum legal size (MLS), National Policy on Mariculture and ecosystem-based management towards the sustainable utilization of marine fisheries resources were well appreciated. Its research initiatives in developing nutraceutical products from marine organisms to treat type 2 diabetes, arthritis, obesity, thyroid and hypertension also played a major role in winning the award. In addition, the institute exhibited leadership in winning several externally funded research projects such as National Brood bank for Cobia and Silver pompano and a Centre of Excellence and Innovation funded by the DBT. The institute also obtained many patents during the period.
Name of ICAR-CMFRI appearing in the ICAR
Foundation Day Award Ceremony Presentation on 16 July 2020
A patent has been granted to ICAR-CMFRI for an invention entitled A process to prepare antidiabetic concentrates from seaweeds and a product thereof (Patent Number 346531) for the term of 20 years from the 19th day of October 2015 in accordance with the provisions of the Patents Act, 1970. CadalminTM ADe is an anti-diabetic nutraceutical, which is effective to combat type-2 diabetes. It contains 100% natural marine bioactive ingredients extracted from selected seaweeds. The bioactive ingredients in CadalminTM ADe competitively inhibit dipeptidyl peptidase-IV and tyrosine phosphatase 1B. The active ingredients of the product decreases production of various mediators responsible for inducing type-2 diabetes, and interfere with the release of simple sugars from the gut, which reduces postprandial hyperglycemia thereby hindering the occurrence of type-2 diabetes. CadalminTM ADe has no side effects as proved from the long-term toxicity studies. The active ingredients purified and concentrated; a total of 350 mg active ingredients in the product are packed in plant-based capsules (cellulose-based hypermelose) to meet the dietary needs of vegetarians. The technology was commercialized during September 2020 to the Pioneer Pharmaceuticals Limited (a Pharmaceutical Company) in Kochi, Kerala, India for commercial production and marketing.